Navigation Links
New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk


Michael S. Singer, M.D., Ph.D.
Harvard Medical School
Contributing Editor

Atherosclerosis is the fundamental process in coronary artery disease, stroke, and many other vascular diseases. It is responsible for more than half of the disease burden of the United States, with an annual cost of over $100 billion. This includes over 1.5 million myocardial infarctions annually. Atherosclerosis technically occurs in everyone 25 and over, but most remain asymptomatic for decades. This underscores the need to identify people at imminent risk for complications, since medication and lifestyle modification can reduce that risk. Well-established risk factors include hypertension, serum cholesterol and lipid levels, diabetes, obesity, diet, tobacco use, and a sedentary lifestyle. Serum levels of homocystine and C-reactive protein also predict risk. More recently, carotid intima-media thickness (CIMT) and the brachial artery reactivity test (BART), both obtained by ultrasound, have been shown to be powerful independent risk factors. Meanwhile, a skin sterol test called PREVU(x) provides a convenient, non-invasive, Point-of-Care assay.

At the root of atherosclerosis is a disturbance of the inner (intimal) wall of the artery. The process is complex, but one component is usually hypertension, which contributes to turbulent blood flow that traumatizes the intimal surface. Another component is inflammation, which combines with lipid, cholesterol, and calcium deposition to form plaques. These plaques accumulate over time, narrow the lumen inside the artery, and limit blood flow to distal structures such as the myocardium and brain. A plaque may also break and liberate pieces that block distal arterial branches. The final common pathway is insufficient blood supply to end organs, which may be acute or chronic.

Despite the central role of the artery in coronary and cerebrovascular disease, it has not been
'"/>




Page: 1 2 3

Related medicine technology :

1. Analyzers Offer Point-of-Care Lipid Panels

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Point Care Methods Measure Coronary and Cerebrovascular Risk
(Date:11/25/2009)... American Scientific Reso...pleased to announce that they have opened a region...hanghai, China. ,, ASR has been able to secure ...for the development and production of current and ... adults to be distributed and sold globally. Curr...
(Date:11/25/2009)...nd, Nov. 25 From November 16-18, ...ring solutions, presented the second edition of th...the special needs of the older population. The con...and audiology from around the world and more than ... with hearing loss for an opportunity to share exp...
(Date:11/25/2009)... 25 AMPAC Fine Chemicals LLC (AFC)...sdaq: APFC ) announced today that it received the...ward at the Annual Statewide Environmental Summit,...hnology Association (CMTA), the Industrial Environ... Council of California (CICC) held in San Diego. ...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3OTCBB VHGI Announces LOI to Sell Certain Assets for 2410 Million Cash Stock to WNDM 3B With Stock Dividend to be Distributed to Shareholders in 2010 6017 1OTCBB VHGI Announces LOI to Sell Certain Assets for 2410 Million Cash Stock to WNDM 3B With Stock Dividend to be Distributed to Shareholders in 2010 6017 2OTCBB VHGI Announces LOI to Sell Certain Assets for 2410 Million Cash Stock to WNDM 3B With Stock Dividend to be Distributed to Shareholders in 2010 6017 3Custom Spine Receives 510k Clearance of Regent ACP 6014 1Custom Spine Receives 510k Clearance of Regent ACP 6014 2Bayer Consumer Care Launches Citracal 28R 29 Calcium Plus Heart Health First Ever Leading Calcium Supplement to Help Support Bone AND Heart Health 6011 1Bayer Consumer Care Launches Citracal 28R 29 Calcium Plus Heart Health First Ever Leading Calcium Supplement to Help Support Bone AND Heart Health 6011 2Bayer Consumer Care Launches Citracal 28R 29 Calcium Plus Heart Health First Ever Leading Calcium Supplement to Help Support Bone AND Heart Health 6011 3
...(BUSINESS WIRE)--Jun 25, 2007 - Neurogen,Corporati...e,results from two dose-ranging, Phase 2b clinical...any,s proprietary insomnia agent,NG2-73, an alpha...rmulations were studied in each trial to determine...maintenance of sleep,through the night without res...
...f.--(BUSINESS WIRE)--Jun 25, 2007 - Gilead,Science...03, a,Phase III clinical trial evaluating the comp...r disoproxil fumarate or tenofovir,DF) 300 mg as a...,(HBV) infection, met its primary efficacy endpoin...e company,s once-daily antiviral,drug Hepsera(R) (...
Other Medicine Technology:Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 2Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 3Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 4Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 5Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 6Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 7Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 8Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
(Date:11/27/2009)... Specialist manufacturers who...ucts are saving millions of dollars by bringing in...ocess. Increasing numbers of pro-active medical ma...ts at the concept stage of their projects, ensurin...g design processes or potentially outdated technol...
(Date:11/26/2009)... , PRINCETON, N.J., Nov. 27 ... almost double over the next 25 years and annual m... $336 billion, up from $113 billion today, accordi...Diabetes Care . The National Changing Diabetes &...ommissioned the analysis by a team from the Univer...
(Date:11/26/2009)...age that,s too big or too heavy can lead to strain...Day News) -- There may be nothing wrong with stuff...t want to do the same thing with your suitcase as ...people were treated in 2008 in U.S. hospital emerg...dical facilities for luggage-related injuries, suc...
(Date:11/26/2009)... Dr. David Kim of the Live Li...surgery in Dallas , is one of a growing number of ...cial networking sites to connect with individuals ...nt to fight morbid obesity. Dr. Kim is utilizing F...mation about his practice with the community. , ...
(Date:11/26/2009)... Ennis & Ennis, P.A. is o... for users of Yaz and Yasmin birth control pills w...monary Embolism, Stroke, Heart Attack or other rel...ed. Women can call toll free at 1-800-856-6405 or ...slaw.com and fill out an online case evaluation f...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3
...g in the October issue of the journal Pediatrics s...lk is more than that of Cow's milk. Dr. Ruth...New York and her colleague Dr. William H. Bowen us... when they were fed sweet liquids like soda and ho...
...ed in the treatment of Multiple Sclerosis (MS), ha...s taking the drug complained of neurological disor...gressive Multifocal Leukoencephalopathy (PML) is b...h work by blocking passage of immune cells in to t...
...rize meant swallowing a glassful of dangerous bact...ssor Barry Marshall however did just that. He swal...ach ulcers are bacterial in origin rather than str...ates for Medicine in the current year. "I didn't t...
...10 countries estimated to have the highest number ...US following closely. Type II Diabetes, one of the...ining // epidemic proportions throughout the world...idity and mortality due to long-term micro and mac...
...as advanced so much to the extent of replacing los...ing artificial implants. These implantable devices...od // alternative to the conventional treatment. ...ality of these tiny, yet useful devices. Designed ...
... been reported at a seniors' home in Toronto and e... have caused the death of four residents at the ho... that there was // no cause to fear an outbreak an... a significant burden of disease," he said. All th...
Other Medicine News:Health News:Nobel For Ulcer-Defying Aussie Scientists 2Health News:A new anti diabetic drug on the anvil 2Health News:Implantable devices to be powered by organosilicon compounds in the future 2
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
Medicine Products: